title: Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.
abstract: Most prostate cancers (PCa) are critically reliant on functional androgen receptor (AR) signaling. At its onset, PCa is androgen-dependent and although temporarily halted by surgically or pharmacologically blocking the AR (androgen ablation), the disease ultimately recurs as an aggressive, fatal castration resistant prostate cancer (CRPC). FDA-approved treatments like docetaxel, a chemotherapeutic agent, and Provenge, a cancer vaccine, extend survival by a scant 3 and 4 months, respectively. It is clear that more effective drugs targeting CRPC are urgently needed. The ErbB family (EGFR/ErbB1, ErbB2/HER2/neu, ErbB3/HER3 and ErbB4/HER4) of receptor tyrosine kinases (RTKs) have long been implicated in PCa initiation and progression, but inhibitors of ErbB1 and ErbB2 (prototypic family members) fared poorly in PCa clinical trials. Recent research suggests that another family member ErbB3 abets emergence of the castration-resistant phenotype. Considerable efforts are being directed towards understanding ErbB3-mediated molecular mechanisms of castration resistance and searching for novel ways of inhibiting ErbB3 activity via rational drug design. Antibody-based therapy that prevents ligand binding to ErbB3 appears promising and fully-humanized antibodies that inhibit ligand-induced phosphorylation of ErbB3 are currently in early development. Small molecule tyrosine kinase inhibitors are also being vigorously pursued, as are siRNA-based approaches and combination treatment strategies- the simultaneous suppression of ErbB3 and its signaling partners or downstream effectors - with the primary purpose of undermining the resiliency of ErbB3-mediated signal transduction. This review summarizes the existing literature and reinforces the importance of ErbB3 as a therapeutic target in the clinical management of prostate cancer.
authors: Department of Urology, University of California Davis, CA. USA.
authors: Maitreyee K
authors: MK
authors: Jathal
authors: Liqun
authors: L
authors: Chen
authors: Maria
authors: M
authors: Mudryj
authors: Paramita M
authors: PM
authors: Ghosh
references: Cancer Biol Ther. 2005 Oct;4(10):1133-7
references: 16138006
references: Clin Cancer Res. 2009 Jan 1;15(1):39-47
references: 19118031
references: BJU Int. 2007 Aug;100(2):303-9
references: 17532856
references: Oncogene. 1997 Nov 27;15(22):2705-16
references: 9400997
references: EMBO J. 2000 Jul 3;19(13):3159-67
references: 10880430
references: BMC Genomics. 2005 Aug 17;6:109
references: 16107210
references: Oncogene. 2009 Feb 12;28(6):803-14
references: 19060928
references: Cancer Res. 2006 Feb 1;66(3):1630-9
references: 16452222
references: Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5
references: 15994225
references: BJU Int. 2005 Dec;96 Suppl 2:41-6
references: 16359438
references: Biochem Biophys Res Commun. 2010 Feb 26;393(1):6-10
references: 20096663
references: Nat Rev Cancer. 2005 May;5(5):341-54
references: 15864276
references: Clin Cancer Res. 2010 Feb 15;16(4):1159-69
references: 20145185
references: J Clin Oncol. 2010 Mar 1;28(7):1124-30
references: 20124187
references: Biochemistry. 2005 Dec 6;44(48):15842-57
references: 16313187
references: Oncogene. 2002 Aug 15;21(36):5609-18
references: 12165860
references: Oncogene. 2007 Jan 18;26(3):462-6
references: 16832345
references: Nat Med. 2002 May;8(5):459-65
references: 11984589
references: Am J Surg Pathol. 1994 Oct;18(10):979-91
references: 7522415
references: Cancer. 1991 Aug 15;68(4):821-8
references: 1906775
references: Cancer Res. 2005 Apr 1;65(7):2547-53
references: 15805247
references: J Natl Med Assoc. 2010 Jun;102(6):500-10
references: 20575216
references: Int J Cancer. 1996 Sep 17;67(6):785-90
references: 8824549
references: Curr Opin Urol. 2009 May;19(3):297-302
references: 19365894
references: Mol Cancer Ther. 2008 Jul;7(7):1880-9
references: 18606718
references: Br J Cancer. 2005 Jan 17;92(1):140-6
references: 15583694
references: Prostate. 1984;5(5):545-57
references: 6483690
references: Curr Drug Metab. 2003 Dec;4(6):487-96
references: 14683476
references: Cancer Cell. 2004 Nov;6(5):517-27
references: 15542435
references: Br J Cancer. 2004 Sep 13;91(6):1190-4
references: 15305194
references: Cancer Res. 2009 Jun 15;69(12):5202-9
references: 19491261
references: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references: 11252954
references: Cancer Res. 2002 Jun 1;62(11):3151-8
references: 12036928
references: Nat Rev Cancer. 2010 Feb;10(2):130-7
references: 20094047
references: Cancer Res. 2007 Jul 15;67(14):6544-8
references: 17638862
references: Cold Spring Harb Symp Quant Biol. 2008;73:491-502
references: 19022743
references: J Biol Chem. 2005 Mar 4;280(9):8238-47
references: 15611073
references: Cancer Res. 2001 Jun 1;61(11):4467-73
references: 11389077
references: Cancer Treat Rev. 2010 Nov;36 Suppl 3:S21-9
references: 21129606
references: Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
references: 16829981
references: Cancer Res. 2010 Jul 15;70(14):5994-6003
references: 20587519
references: Cancer. 2002 Feb 15;94(4):980-6
references: 11920466
references: Urology. 1997 Mar;49(3A Suppl):16-22
references: 9123731
references: Nat Neurosci. 2001 Apr;4(4):374-81
references: 11276227
references: Oncogene. 2000 Nov 16;19(48):5471-6
references: 11114724
references: Am J Pathol. 1995 Jun;146(6):1368-75
references: 7778676
references: Cancer Res. 2006 Nov 1;66(21):10613-20
references: 17079486
references: Clin Cancer Res. 1995 May;1(5):473-80
references: 9816006
references: Cancer Res. 2010 Mar 15;70(6):2485-94
references: 20215504
references: J Pathol. 2004 Jun;203(2):688-95
references: 15141384
references: Methods Mol Biol. 2009;472:439-53
references: 19107447
references: Am J Clin Oncol. 2010 Dec;33(6):609-13
references: 20042973
references: Clin Cancer Res. 2009 Feb 15;15(4):1133-9
references: 19228718
references: Cancer Cell. 2009 May 5;15(5):429-40
references: 19411071
references: J Biol Chem. 2007 Nov 9;282(45):32689-98
references: 17823122
references: Cancer Cell Int. 2008 Nov 24;8:18
references: 19025630
references: Nat Rev Cancer. 2009 Jul;9(7):463-75
references: 19536107
references: Cancer Control. 2004 Nov-Dec;11(6):364-73
references: 15625524
references: CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40
references: 4625049
references: Cancer Res. 2000 Dec 15;60(24):6841-5
references: 11156376
references: Semin Oncol. 2001 Oct;28(5 Suppl 16):80-5
references: 11706399
references: BMC Cancer. 2007 Jul 27;7:142
references: 17662137
references: J Natl Cancer Inst. 1999 Nov 3;91(21):1869-76
references: 10547394
references: Onkologie. 2007 Jul;30(7):355-60
references: 17596743
references: Oncogene. 2003 Jun 5;22(23):3598-607
references: 12789268
references: Ann Oncol. 2002 Jan;13(1):65-72
references: 11863114
references: Mol Cancer Ther. 2005 Apr;4(4):505-15
references: 15827323
references: Exp Cell Res. 2003 Mar 10;284(1):89-98
references: 12648468
references: Mol Cell Biol. 2004 Sep;24(17):7748-57
references: 15314180
references: Oncogene. 1999 Jan 21;18(3):731-8
references: 9989823
references: Stem Cells. 1998;16(6):413-28
references: 9831867
references: Rev Urol. 2001;3 Suppl 3:S10-4
references: 16986003
references: Cancer Cell. 2002 Aug;2(2):127-37
references: 12204533
references: Clin Cancer Res. 2006 May 1;12(9):2730-7
references: 16675564
references: Clin Genitourin Cancer. 2007 Dec;5(7):433-7
references: 18272025
references: Cancer Res. 2007 Dec 15;67(24):11924-32
references: 18089823
references: Clin Cancer Res. 2008 Jun 15;14(12):3729-36
references: 18559590
references: Mol Cancer Res. 2007 Jul;5(7):675-84
references: 17634423
references: Prostate. 1993;22(1):65-74
references: 8426839
references: BJU Int. 2005 Jun;95(9):1320-6
references: 15892825
references: Cancer Res. 2006 Dec 1;66(23):11279-86
references: 17145873
references: Anticancer Res. 2000 Jan-Feb;20(1A):91-5
references: 10769639
references: Clin Prostate Cancer. 2003 Jun;2(1):50-7
references: 15046685
references: Nature. 1997 Oct 16;389(6652):725-30
references: 9338783
references: Mol Cell Endocrinol. 2001 Apr 25;175(1-2):185-91
references: 11325528
references: Nature. 2007 Jan 25;445(7126):437-41
references: 17206155
references: Endocr Relat Cancer. 2005 Mar;12(1):119-34
references: 15788644
references: Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8880-5
references: 12072561
references: Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5958-62
references: 8650201
references: Cancer Res. 2009 Apr 1;69(7):2941-9
references: 19318561
references: Tumori. 2004 Mar-Apr;90(2):163-70
references: 15237576
references: Med Care. 2010 Oct;48(10):915-22
references: 20733530
references: Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10917-22
references: 16832058
references: J Chemother. 2004 Nov;16 Suppl 4:44-8
references: 15688609
references: Br J Cancer. 2007 Aug 20;97(4):453-7
references: 17667926
references: Clin Cancer Res. 1999 Aug;5(8):2171-7
references: 10473102
references: Prostate. 2004 Sep 1;60(4):332-7
references: 15264245
references: Cancer Cell. 2010 Jan 19;17(1):77-88
references: 20129249
references: Oncogene. 2007 May 24;26(24):3503-10
references: 17173075
references: Cancer Lett. 2003 Mar 20;192(1):67-74
references: 12637154
references: Curr Cancer Drug Targets. 2007 Sep;7(6):591-604
references: 17896924
references: Cancer Res. 2005 Apr 15;65(8):3404-9
references: 15833875
references: Nat Med. 1999 Mar;5(3):280-5
references: 10086382
references: J Clin Oncol. 2007 Jan 20;25(3):257-62
references: 17235043
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: Cancer Res. 2008 Nov 15;68(22):9221-30
references: 19010894
references: J Biol Chem. 2002 Mar 15;277(11):8961-9
references: 11779863
references: FEBS Lett. 1999 Mar 26;447(2-3):227-31
references: 10214951
references: Br J Cancer. 2000 Feb;82(3):683-90
references: 10682683
references: Int J Cancer. 2005 Jul 1;115(4):519-27
references: 15704104
references: Cancer. 2004 May 15;100(10):2125-31
references: 15139054
references: Nat Rev Drug Discov. 2010 Jul;9(7):513-4
references: 20592741
references: Cancer Res. 1994 Jul 1;54(13):3594-601
references: 8012987
references: Cancer Res. 2010 Feb 1;70(3):1204-14
references: 20103628
references: Cancer Res. 2007 Sep 1;67(17):7960-5
references: 17804702
references: Oncol Rep. 2007 Nov;18(5):1321-7
references: 17914592
references: Br J Cancer. 2010 Feb 2;102(3):457-61
references: 20010942
references: Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64
references: 16163160
references: Prostate. 1993;23(2):149-64
references: 8378188
references: Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7692-7
references: 20351256
references: Mol Cancer Ther. 2008 Oct;7(10):3176-86
references: 18852121
references: Cancer Res. 1998 Jul 15;58(14):3009-14
references: 9679964
references: Cancer. 1999 Apr 15;85(8):1822-7
references: 10223578
references: Prostate. 1989;15(3):233-50
references: 2555799
references: Nat Rev Cancer. 2001 Oct;1(1):34-45
references: 11900250
references: Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2866-71
references: 11867753
references: Oncogene. 2004 Feb 12;23(6):1197-205
references: 14647450
references: Cancer Gene Ther. 2008 Jul;15(7):413-48
references: 18404164
references: Clin Cancer Res. 2005 Mar 1;11(5):1704-12
references: 15755991
references: BMC Cancer. 2009 May 11;9:142
references: 19432987
references: Int J Cancer. 2009 Dec 1;125(11):2565-75
references: 19530240
references: Annu Rev Pharmacol Toxicol. 2004;44:195-217
references: 14744244
references: Cancer Sci. 2011 Jan;102(1):51-6
references: 21091846